Jeremy Frissell
Surgical · Smithfield, RINPI 1790707800
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,600 of the $2,211 with a category attached, or 72.4%. Medtronic accounts for 81.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $1,820 and has fallen 90.5% since, to $173 in 2025. Among surgical clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $85.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$236
- Daiichi Sankyo Inc.$60
- Ardelyx, Inc.$56
- Lilly USA, LLC$17
- Currax Pharmaceuticals LLC$16
- plus $26 from 2 others
What the payments were for
- Consulting fees$1,60072%
- Travel & lodging$2019%
- Food & beverage$41019%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 6 | $1,801 |
| Novo Nordisk | 11 | $236 |
| Daiichi Sankyo Inc. | 3 | $60 |
| Ardelyx, Inc. | 2 | $56 |
| Lilly USA, LLC | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $12 |
How this compares
$2,211 in reported general payments places this provider in the 95th percentile of 41 surgical providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WegovySemaglutide | 19 | $24,780 |
| LinzessLinaclotide | 28 | $18,322 |
| Ursodiol | 28 | $2,480 |
| Omeprazole | 111 | $1,890 |
| CholestyramineCholestyramine (With Sugar) | 13 | $1,280 |
| Sucralfate | 26 | $1,119 |
| Ec-NaproxenNaproxen | 23 | $948 |
| Nystatin | 22 | $597 |
| LoperamideLoperamide Hcl | 36 | $573 |
| Naproxen | 11 | $449 |
| Celecoxib | 21 | $262 |
| Famotidine | 13 | $252 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 16 | $199 |
| Promethazine Hcl | 20 | $164 |
| Tramadol Hcl | 56 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskWegovy | $236 | $24,78019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 surgical providers in Rhode Island.
Other surgical in Smithfield
- Bradley HuntPawtucket$3K
- Philip ZingaleJohnston$2K
- Stacie BrzoskaWakefield$2K
- Ryan O'KellyWarwick$2K
- Emma BanksPawtucket$2K
- Jennifer PinhancosProvidence$1K
- Shana LibassiEast Greenwich$1K
- Peter MelloProvidence$1K
- Lindsay LichtenfelsWarwick$817
- Michelle RistucciaWarwick$748
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.